Best Foundayo (Orforglipron) Providers in 2026 — Ranked & Reviewed
Eli Lilly won approval for Foundayo (orforglipron) on April 1, 2026, making it the first oral GLP-1 receptor agonist to hold FDA approval in chronic weight management. Commercial dispensing began on April 6, 2026. The provider list is still short and growing quickly. We track each US telehealth platform, and each pharmacy, confirmed as a Foundayo channel, verifying the pricing tiers on each provider's own website. A commercially insured patient using the Lilly Savings Card pays $25/month; cash-pay runs $149-$299/month. This page is updated weekly as further providers come online.
Lowest verified price: $149/mo9 providers compared
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
9 foundayo (orforglipron) providers compared · independently scored against our six-factor methodology.
Compare the top providers at a glance
Every row carries a logo, our editorial rating, price, the medications prescribed, and where the seller ships. Scan down a column and the list shortens fast.
- ★ Editor's Pick
oral orforglipron alongside the injectables
From /mo$149Coverage36 statesMedicationsSemaglutideTirzepatideOrforglipron - Best Budget
oral orforglipron alongside the injectables
From /mo$25Scales with doseCoverage50 statesMedicationsOrforglipron - Nationwide Coverage
oral orforglipron alongside the injectables
From /mo$25Coverage50 statesMedicationsOrforglipron oral orforglipron alongside the injectables
From /mo$149Scales with doseCoverage50 statesMedicationsOrforglipronTirzepatidetirzepatide from $299/month
From /mo$149CoverageCheck intakeMedicationsTirzepatideSemaglutideOrforglipronknowing which pharmacy fills the vial — it names Roman Health Pharmacy LLC
From /mo$149CoverageCheck intakeMedicationsOrforglipronoral orforglipron alongside the injectables
From /mo$149CoverageCheck intakeMedicationsSemaglutideTirzepatideOrforglipronoral orforglipron alongside the injectables
From /mo$149CoverageCheck intakeMedicationsSemaglutideTirzepatideOrforglipron
| Provider | Rating | From /mo | Medications | Coverage | |
|---|---|---|---|---|---|
★ Editor's Pick oral orforglipron alongside the injectables | $149 | SemaglutideTirzepatideOrforglipron | 36 states | Visit → | |
Best Budget oral orforglipron alongside the injectables | $25 Scales by dose | Orforglipron | 50 states | Visit → | |
Nationwide Coverage oral orforglipron alongside the injectables | $25 | Orforglipron | 50 states | Visit → | |
 oral orforglipron alongside the injectables | $149 Scales by dose | OrforglipronTirzepatide | 50 states | Visit → | |
 tirzepatide from $299/month | $149 | TirzepatideSemaglutideOrforglipron | Check intake | Visit → | |
 knowing which pharmacy fills the vial — it names Roman Health Pharmacy LLC | $149 | Orforglipron | Check intake | Visit → | |
 oral orforglipron alongside the injectables | $149 | SemaglutideTirzepatideOrforglipron | Check intake | Visit → | |
 oral orforglipron alongside the injectables | $149 | SemaglutideTirzepatideOrforglipron | Check intake | Visit → |
A seller that will not show a price before an intake loses points on Value and carries that note in its review. Withholding the number is itself a finding. How we score →
Detailed Reviews
PreventiveMD
Best for: oral orforglipron alongside the injectables
All-in figures start at $83/mo for compounded semaglutide and $97/mo for compounded tirzepatide. Foundayo, Zepbound and Wegovy come as brands under a membership arrangement. Requests reach a US-licensed provider inside 24 hours, and once approved the drug is sent to your door with care continuing through a portal online. Peptide therapy shares the platform with the GLP-1 side, all physician-guided.
Score Breakdown
Pros
- ✓Semaglutide at $149 a month, 89% below the $1299 median for the same drug and form across this register
- ✓Tirzepatide at $299 a month, 76% below the $1249 median for the same drug and form across this register
- ✓Publishes a price on its own site before the medical questionnaire, so it can be compared without handing over health information
- ✓The monthly figure covers medication and consult
- ✓No FDA warning letter matched this operator when we searched our enforcement register
Cons
- ✗Coverage is published for 36 states only, so this may not reach you
- ✗No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
- ✗Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
LillyDirect Foundayo
Best for: oral orforglipron alongside the injectables
Any licensed prescriber can write it, but LillyDirect will not ship without a valid US prescription. Eli Lilly runs this channel itself, direct-pay, and what it sells is Foundayo (orforglipron): for weight loss, the first oral GLP-1 pill. Commercially insured patients holding the Lilly Savings Card pay $25/month. Paying cash costs $149-$299/month, depending on labeled dose.
Score Breakdown
Pros
- ✓Orforglipron at $149 a month, within the normal band around this register's $149 median for the same drug and form
- ✓Publishes a price on its own site before the medical questionnaire, so it can be compared without handing over health information
- ✓Coverage is published for all 50 states
- ✓No FDA warning letter matched this operator when we searched our enforcement register
Cons
- ✗No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
Amazon One Medical
Best for: oral orforglipron alongside the injectables
Amazon runs its GLP-1 business through a single unified channel here. Prescribing sits with One Medical clinicians and covers three FDA-approved drugs, Foundayo, Zepbound, and Wegovy, with nothing compounded on the list. Fulfillment is Amazon Pharmacy: same-day delivery in roughly 3,000 US cities, or pickup kiosks at select One Medical locations. Membership beforehand is not a prerequisite, and cash pay and insurance are both accepted. Foundayo launched at $25/month for patients with insurance and the Lilly Savings Card, $149/month paying cash.
Score Breakdown
Pros
- ✓Orforglipron at $149 a month, within the normal band around this register's $149 median for the same drug and form
- ✓Publishes a price on its own site before the medical questionnaire, so it can be compared without handing over health information
- ✓The monthly figure covers consult and shipping
- ✓Coverage is published for all 50 states
- ✓No FDA warning letter matched this operator when we searched our enforcement register
- ✓Baseline bloodwork is required before a prescription
Cons
- ✗Billed separately from the monthly figure: medication, labs
- ✗No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
GoodRx
Best for: oral orforglipron alongside the injectables
GoodRx (NASDAQ: GDRX) is the largest US prescription savings platform. It publishes self-pay discount pricing on brand-name GLP-1 medications, with Foundayo (orforglipron) starting at $149/month and the Zepbound KwikPen (tirzepatide) starting at $299/month, redeemable at 70,000+ pharmacies nationwide. It also operates GoodRx Care, a telehealth arm that prescribes GLP-1s with online visits starting at $39.
Score Breakdown
Pros
- ✓Tirzepatide at $299 a month, 76% below the $1249 median for the same drug and form across this register
- ✓Coverage is published for all 50 states
- ✓No FDA warning letter matched this operator when we searched our enforcement register
Cons
- ✗No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
PrideRx
Best for: tirzepatide from $299/month
The first month of membership costs $25; after that it is $99/mo, buying doctor visits and prescription management while the pharmacy invoices the drug on its own. Only brand-name GLP-1 products are sold: Foundayo (orforglipron) at $149/mo, oral semaglutide as the Wegovy Pill at $149/mo too, and Zepbound (tirzepatide) from $299/mo, each fulfilled straight through LillyDirect and NovoCare. PrideRx presents itself as LGBTQ+-friendly and also handles sexual health, PrEP and hair loss.
Score Breakdown
Pros
- ✓Tirzepatide at $299 a month, 76% below the $1249 median for the same drug and form across this register
- ✓Publishes a price on its own site before the medical questionnaire, so it can be compared without handing over health information
- ✓No FDA warning letter matched this operator when we searched our enforcement register
Cons
- ✗No state list is on record here, so whether it serves your state cannot be confirmed from this page
- ✗No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
Buying Foundayo (orforglipron): what to verify
Foundayo is the first oral GLP-1 pill the FDA has approved for weight loss, and only a small dispensing channel exists so far. It is one Lilly product. The entries here separate on access, on price, and on whether a seller is a real channel for it at all.
What to check
- A verified channel for the real product. Specific pharmacies dispense this drug. A seller either sits inside that channel or it does not, and the distinction is checkable. Compounded orforglipron is not a legitimate product, and no listing offering one belongs in this category.
- Whether the Lilly savings card gets applied. For commercially insured patients who qualify, the manufacturer savings card cuts the monthly cost substantially. Applying it is something a seller does or omits, and an omission usually goes unmentioned.
- An intake a clinician actually reads. This is a prescription drug, and the review behind it is meant to be a medical one. Approval issued in seconds, with nobody reachable afterward, describes a storefront rather than a practice.
Red flags
- Pharmacy unnamed and no LegitScript listing. Two disclosures are checkable on any compounded-GLP-1 seller: the 503A or 503B pharmacy filling the vial, and a LegitScript certification. When a site publishes neither, nothing about the contents of that vial can be confirmed from outside.
- Instant approval with no clinician you can reach. A prescriber is supposed to read the intake and stay available once dose questions start. Approval issued automatically, with nobody reachable afterward, means the medical layer was removed rather than streamlined.
- The advertised number is a first month. Headline figures here are usually qualified somewhere. Common forms are an opening rate that steps up with each dose increase, and a membership fee billed separately from the drug itself. Either one can double what leaves your account in month two.
- B12, MIC, or HCG sold for weight loss. Trial evidence for weight loss sits with the GLP-1 injections and nowhere else on this aisle. A clinic that lists lipotropic, B12, or HCG shots under weight loss is selling past the record, whatever its own site says.
Every seller listed above is scored on these criteria under our six-dimension methodology, with prices re-checked against the seller’s own live site.
How we rank, and what counts as “legit”
Scoring for every provider on this page runs against our published six-factor rubric[1]: value, effectiveness, user experience, trust & safety, accessibility and support.
Each of Wegovy, Zepbound, Ozempic and Mounjaro holds its own separate FDA approval under its own NDA number[4][5]. Published Phase 3 efficacy for semaglutide at 2.4 mg (~14.9% mean weight loss across 68 weeks) comes from STEP 1[6]; those for tirzepatide (~20.9% at the 15 mg dose over 72 weeks) come from SURMOUNT-1[7]. In 2025 the SURMOUNT-5 head-to-head set the two against each other[8].
How much of an anti-obesity medication is covered varies widely between state Medicaid programs and between commercial plans[9][10]. Under IRS Publication 502, compounded GLP-1s and brand-name ones alike are generally FSA/HSA eligible where a prescription exists[11].
Frequently Asked Questions
Glossary
The words sellers use, defined. Tap any term.
- Orforglipron · Drugs and brands
- Foundayo · Drugs and brands
- Wegovy · Drugs and brands
- Zepbound · Drugs and brands
- GLP-1 receptor · Mechanism
- STEP-1 · Major trials
- Compounded GLP-1 · Pharmacy and drug forms
Sources & methodology — as of August 2026
- 1.GLP Watchdog — GLP-1 Pricing Index 2026 (our independent dataset)— GLP Watchdog.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 5.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 8.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
- 9.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 10.CMS — Medicaid prescription drug coverage policy (state-by-state)— Centers for Medicare & Medicaid Services.
- 11.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.